Fast-acting edible peaked earlier, with no other significant active-product…
Pharmacokinetic Differences Between Fast-Acting, Standard, and Placebo Cannabis Edibles.
AI Summary
This study asked whether a fast-acting cannabis edible reaches peak blood concentrations sooner than a standard edible. Twenty participants completed a within-subjects comparison of a fast-acting edible, a standard edible, and a THC-free placebo designed to resemble the active products. Researchers measured THC and related compounds in blood plasma, including time to peak concentration (Tmax), maximum concentration, half-life, and overall exposure.
The fast-acting edible reached peak concentration 30 minutes after ingestion, on average 30 minutes earlier than the standard edible. The two THC-containing edibles did not significantly differ in maximum concentration, half-life, or overall exposure; both differed significantly from placebo across the measured pharmacokinetic parameters. The authors attribute the faster peak to the fast-acting product’s microencapsulation technology. This abstract-based summary is limited to blood-level measurements: it cannot establish whether the faster peak changes perceived effects, safety, or real-world dose management.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More THC research papers you might find interesting.
Small lab study finds cannabis affected simulated driving and confidence
A lab method measures 17 cannabinoids across five hemp product types
A single-center study finds varied care and no recurrence in follow-up
Explore More Research
Stay informed about the latest cannabis science.